I am very grateful to the Backbench Business Committee for affording me the opportunity to make a statement on the publication of the Scottish Affairs Committee’s third report of this Session, on the pilot safer drug consumption facility in Glasgow’s east end. Despite a reduction in deaths this year, Scotland continues to face the highest rate of drug-related deaths in Europe. Without a doubt, that is the most pressing public health issue facing Scotland, and it is in that context that the Committee agreed to undertake a thorough examination of the pilot facility on Hunter Street, called the Thistle.
The Committee’s inquiry follows up on excellent work conducted by our predecessor Committee on problem drug use in Scotland, and I take this opportunity to express our thanks to everyone who contributed to this inquiry, in particular Dr Saket Priyadarshi and the team at the Thistle for their continued engagement with our work. This is a challenging issue, and I express my gratitude to the members of the Scottish Affairs Committee for their thoughtful and collaborative work on this report.
In 2024, some 1,017 people died from drug-related causes—a figure expected to rise in 2025—with the highest concentration of deaths occurring in the Glasgow city area. The problem is not new. High levels of drug deaths have been a concern in the city for over a decade, and other harms, such as the transmission of blood-borne viruses, remain prevalent. Between 2014 and 2020, an outbreak of HIV among people who inject drugs saw 188 new diagnoses reported in the Greater Glasgow area. To address those harms, Glasgow city health and social care partnership, NHS Greater Glasgow and Clyde and other partners launched the Thistle, the UK’s first sanctioned safer drug consumption facility.
The Thistle was opened as a three-year pilot. At the Thistle, visitors can self-administer drugs in safe, hygienic conditions under medical supervision. Staff can reverse overdoses, treat wounds and provide hygienic injecting equipment. Of equal importance to the immediate medical harm reduction is the space the facility provides for expert clinicians to build trusting relationships with people whom it would otherwise be hard for support services to reach. Those relationships can be a pathway to engagement with other health and social services, such as drug treatment, counselling and housing services, which can help address the drivers of problem drug use.
When we visited the facility shortly after it opened, we were particularly impressed by the expertise and dedication of the staff we met. The opening of the Thistle marks a radical change in approach to drug use in the UK, but internationally, safer drug consumption facilities are not uncommon; similar facilities already operate in 60 cities across the world. None of those facilities have ever reported an overdose death on the premises.
As part of our inquiry, we visited Norway and Lisbon. We saw how safer drug consumption facilities have been a core part of Portugal’s strategy to reduce drug harms. We looked carefully at what Portugal has done, given that it has achieved a radical reduction in drug harms; it has achieved an 80% reduction in the number of drug-related deaths over the past 20 years. We also travelled to Oslo and Bergen, where we saw how facilities can be successfully integrated into local communities. Above all else, our report calls on the UK Government to adopt an evidence-based approach, and not to make up their mind about the Thistle before the trial has concluded. To that end, our report also argues that experts in the evidence, rather than those with preconceived ideas, should determine the facility’s future.